drugset
Drugs / Diamyd
last change Jul 2026 re-read 3 minutes ago

Diamyd

also known as GAD-Alum

Protein / enzyme biologic

Developed for
type 1 diabetes mellitus
Investigated by
Diamyd Medical AB

Trials 1

today NCT05683990 · Ph 2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05683990 Jul 2024 → Mar 2028 expected type 1 diabetes mellitus Diamyd Medical AB Active not recruiting No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT01122446 Comparator Apr 2009 → Dec 2016 prediabetes syndrome, type 1 diabetes mellitus Lund University Completed No outcome recorded

Press releases naming this drug 24 releases

DateIssuerRelease
2026-07-27 Diamyd Therapeutics AB Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis diamyd.com ↗
2026-06-25 Diamyd Therapeutics AB Mathias Skalmstad new CFO at Diamyd Medical diamyd.com ↗
2026-06-23 Diamyd Therapeutics AB Diamyd Medical provides update on Strategic Review diamyd.com ↗
2026-06-18 Diamyd Therapeutics AB Diamyd Medical announces update regarding interim CFO diamyd.com ↗
2026-06-11 Diamyd Therapeutics AB Diamyd Medical receives Notice of Allowance for Key Precision Medicine Patent diamyd.com ↗
2026-06-05 Diamyd Therapeutics AB Diamyd Medical provides update on ongoing Activities diamyd.com ↗
2026-05-22 Diamyd Therapeutics AB Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company diamyd.com ↗
2026-05-20 Diamyd Therapeutics AB Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use diamyd.com ↗
2026-05-11 Diamyd Therapeutics AB Diamyd Medical provides an update on strategic review and financial position diamyd.com ↗
2026-05-05 Diamyd Therapeutics AB Diamyd Medical strengthens its position in the manufacturing of biological medicines – positive feedback from the Swedish Medical Products Agency diamyd.com ↗
2026-04-24 Diamyd Therapeutics AB Diamyd Medical announces governance and leadership update diamyd.com ↗
2026-04-23 Diamyd Therapeutics AB Diamyd Medical announces governance and leadership changes diamyd.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Diamyd ClinicalTrials.gov intervention name — accepted as the source's own label NCT01122446 ↗
1

NCT05683990 ↗
Known as GAD-Alum “We investigated if autoantigen-specific treatment with alum-formulated glutamate decarboxylase (GAD-Alum) was safe and affected progression to type 1 diabetes in children with...” PMID 29171140 ↗ Nov 2017
Modality Protein / enzyme biologic “autoantigen-specific treatment with alum-formulated glutamate decarboxylase (GAD-Alum)” PMID 29171140 ↗ Nov 2017
Route Subcutaneous “GAD-Alum as a subcutaneous prime and boost injection” PMID 29171140 ↗ Nov 2017